JP2018203735A5 - - Google Patents

Download PDF

Info

Publication number
JP2018203735A5
JP2018203735A5 JP2018104357A JP2018104357A JP2018203735A5 JP 2018203735 A5 JP2018203735 A5 JP 2018203735A5 JP 2018104357 A JP2018104357 A JP 2018104357A JP 2018104357 A JP2018104357 A JP 2018104357A JP 2018203735 A5 JP2018203735 A5 JP 2018203735A5
Authority
JP
Japan
Prior art keywords
antibody
binding protein
fragment
seq
isolated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018104357A
Other languages
English (en)
Japanese (ja)
Other versions
JP7222614B2 (ja
JP2018203735A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018203735A publication Critical patent/JP2018203735A/ja
Publication of JP2018203735A5 publication Critical patent/JP2018203735A5/ja
Application granted granted Critical
Publication of JP7222614B2 publication Critical patent/JP7222614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018104357A 2017-05-31 2018-05-31 抗jagged1抗原結合タンパク質 Active JP7222614B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512805P 2017-05-31 2017-05-31
US62/512,805 2017-05-31

Publications (3)

Publication Number Publication Date
JP2018203735A JP2018203735A (ja) 2018-12-27
JP2018203735A5 true JP2018203735A5 (enExample) 2021-07-26
JP7222614B2 JP7222614B2 (ja) 2023-02-15

Family

ID=62683483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018104357A Active JP7222614B2 (ja) 2017-05-31 2018-05-31 抗jagged1抗原結合タンパク質

Country Status (23)

Country Link
US (3) US11028180B2 (enExample)
EP (1) EP3630820A1 (enExample)
JP (1) JP7222614B2 (enExample)
KR (1) KR20200012848A (enExample)
CN (1) CN110621695B (enExample)
AR (1) AR111767A1 (enExample)
AU (1) AU2018275231B2 (enExample)
BR (1) BR112019023118A2 (enExample)
CA (1) CA3059975A1 (enExample)
CL (1) CL2019003167A1 (enExample)
CO (1) CO2019012204A2 (enExample)
CR (1) CR20190513A (enExample)
EA (1) EA201992348A1 (enExample)
JO (1) JOP20190259A1 (enExample)
MA (1) MA48777A (enExample)
MX (1) MX2019013211A (enExample)
PE (1) PE20200487A1 (enExample)
PH (1) PH12019502449A1 (enExample)
SG (1) SG11201909529XA (enExample)
TW (1) TW201908339A (enExample)
UY (1) UY37752A (enExample)
WO (1) WO2018222770A1 (enExample)
ZA (1) ZA201906821B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102030891B1 (ko) * 2014-02-12 2019-10-11 제넨테크, 인크. 항-재기드1 항체 및 사용 방법
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CN111471643B (zh) * 2020-04-09 2020-12-29 创芯国际生物科技(广州)有限公司 一种通用型上呼吸道粘膜类器官的培养基及培养方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992022646A1 (en) 1991-06-14 1992-12-23 Dnx Corp. Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
DE69732667T2 (de) 1996-12-12 2006-01-19 Prolume, Ltd., Beverly Hills Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
EP2155249A4 (en) 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
WO2009124931A2 (en) * 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20130309246A1 (en) * 2011-02-02 2013-11-21 The Trustees Of Princeton University Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
CA2876904C (en) * 2012-06-22 2019-12-03 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
US10350216B2 (en) * 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
WO2014151866A1 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
KR102030891B1 (ko) * 2014-02-12 2019-10-11 제넨테크, 인크. 항-재기드1 항체 및 사용 방법
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
KR101599370B1 (ko) * 2014-04-24 2016-03-03 한국생명공학연구원 Jagged 1에 대한 인간 단일클론항체 J1J22
JP2018510150A (ja) * 2015-03-06 2018-04-12 ソレント・セラピューティクス・インコーポレイテッド Jag1に結合する抗体医薬
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Similar Documents

Publication Publication Date Title
JP2019504032A5 (enExample)
JP2022031635A5 (enExample)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP2020517249A5 (enExample)
JP2018521638A5 (enExample)
JP2025016349A5 (enExample)
JP2018183173A5 (enExample)
JP2018108081A5 (enExample)
JP2020079252A5 (enExample)
JP2020500538A5 (enExample)
JP2019122405A5 (enExample)
JP2010516229A5 (enExample)
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2012504955A5 (enExample)
HRP20171690T1 (hr) Antitijela koja se vežu za humani cgrp receptor
JP2012513214A5 (enExample)
JP2018522541A5 (enExample)
RU2013110874A (ru) Антитела против il-18r1 и их применения
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2017536354A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
NZ717476A (en) Anti-garp protein and uses thereof
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2020524661A5 (enExample)